AtRial Cardiopathy and Antithrombotic Drugs In prevention After crytogenic stroke Cognition and Silent Infarcts (Cognition and Silent Infarcts)

About this Study

This is an ancillary study to the ARCADIA trial. It will assess cognitive function and silent infarcts in a subset of the ARCADIA population.  Patients randomized in ARCADIA  will be eligible for ARCADIA-CSI if they can undergo cognitive testing and have no MRI contraindications.The purpose of the study is to determine the effect of apixaban vs. aspirin on these two additional outcomes in patients with stroke of unknown cause and atrial cardiopathy.

Sponsor Protocol ID:2019-0280
IRB Number:2019-0280
Actively Enrolling
Interventional
Early Phase 1
January 27, 2020
Eligibility Criteria
Both Male and Female
No
No
No

Exclusion CriteriaHistory of traumatic brain injury with loss of consciousness of more than 30 minutes

Education less than 8 years

Known active illicit drug use

Diagnosis of dementia